Guillain-Barre Syndrome Drugs Market Report 2025

The guillain-barre syndrome drugs market size has grown strongly in recent years. It will grow from $1.17 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to progress in the field of research and development, governmental programs and assistance with regulations, increased focus on neurology and autoimmune diseases, increased focus on reducing healthcare costs, and growth in demand for hospital and clinic services.

The guillain-barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the growing rate of guillain-barre syndrome (GBS) incidence, increasing recognition and recognition rates, growing geriatric population, increasing role of hospital pharmacies and retail pharmacies, and growing demand for oral and parenteral medications. Major trends in the forecast period include the development of new therapies, advancements in diagnostic tools, collaboration between pharmaceutical companies and research institutions, advancements in gene therapy, and advancements in intravenous immunoglobulin therapy.

The forecast of 7% growth over the next five years reflects a modest reduction of 0.9% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions may burden U.S. neurology clinics by inflating costs of intravenous immunoglobulin (IVIG) therapies and nerve conduction study equipment imported from Germany and Australia, increasing acute neuropathy treatment costs and rehabilitation expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The expected surge in demand for personalized medicine is set to drive growth in the Guillain-Barre syndrome drugs market. Personalized medicine involves customizing medical treatments based on individual characteristics such as genetics or lifestyle to optimize effectiveness and minimize side effects. This demand is fueled by the potential for more efficient treatments, advancements in genomics, the increasing complexity of diseases, and regulatory backing. In Guillain-Barre syndrome (GBS), personalized medicine aims to tailor treatments according to individual patient profiles, improving therapeutic outcomes and reducing adverse effects. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases, up from six in 2022, as reported by the US-based non-profit organization, Personalized Medicine Coalition. This trend underscores how the rising preference for personalized medicine is pushing growth in the Guillain-Barre syndrome drugs market.

Key players in the guillain-barre syndrome drugs market are innovating by developing products such as humanized monoclonal antibodies to maintain their market presence. Humanized monoclonal antibodies are lab-made antibodies that combine human antibodies with parts of mouse or rat monoclonal antibodies. They are explored as potential therapies due to their ability to target specific immune system components involved in GBS pathology. For example, in October 2023, Annexon Inc., a US-based biopharmaceutical company, announced that ANX005 received orphan drug designation from the European Medicines Agency (EMA) and the FDA for GBS treatment. ANX005, a humanized monoclonal antibody, works by inhibiting C1q to halt complement-mediated inflammation and neuronal damage in early-stage GBS. Annexon has completed target enrollment in a Phase 3 trial of ANX005 in GBS, with top-line data expected in the first half of 2024. ANX005 aims to mitigate inflammation and nerve damage by selectively blocking C1q activity in the nervous system, promoting rapid cessation of autoimmune damage and muscle strength recovery in GBS patients.

In April 2022, Grifols SA, a Spanish pharmaceutical company, acquired Biotest AG for $1.17 billion, aiming to expand and diversify its plasma supply. This strategic move also strengthens Grifols' presence and revenues in Europe, the Middle East, and Africa, while fostering collaboration between Grifols and Biotest to improve global access to plasma-derived therapies. Biotest AG, based in Germany, provides drugs for Guillain-Barre syndrome (GBS) treatment.

Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc.

North America was the largest region in the Guillain-Barre syndrome drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the guillain-barre syndrome drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Guillain-Barre syndrome drugs market consists of sales of monoclonal antibodies, cell therapies, and recombinant enzymes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The Guillain-Barre syndrome drugs market research report is one of a series of new reports that provides Guillain-Barre syndrome drugs market statistics, including Guillain-Barre syndrome drugs industry global market size, regional shares, competitors with a Guillain-Barre syndrome drugs market share, detailed Guillain-Barre syndrome drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Guillain-Barre syndrome drugs industry. This Guillain-Barre syndrome drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Guillain-Barre syndrome drugs are medications designed to address the symptoms and complications associated with Guillain-Barre syndrome (GBS), an autoimmune condition characterized by the immune system attacking the nervous system. These drugs primarily target modulating the activity of the peripheral immune system to slow down the disease's progression and alleviate its symptoms.

The primary classes of Guillain-Barre syndrome drugs include immunoglobulins (IVIG), corticosteroids, and plasma exchange. Intravenous immunoglobulin (IVIG) is a medication derived from pooled human blood plasma containing a high concentration of antibodies. It is used as a first-line treatment and in adjunctive or supportive therapy, finding widespread use in clinics, hospitals, and other medical settings.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.